Ultragenyx Pharmaceutical (NASDAQ:RARE) reported quarterly losses of $(1.39) per share which missed the analyst consensus estimate of $(1.29) by 7.75 percent. This is a 8.55 percent increase over losses of $(1.52) per share from the same period last year. The company reported quarterly sales of $164.877 which missed the analyst consensus estimate of $155.393 million by 100.00 percent. This is a 100.00 percent decrease over sales of $127.392 million the same period last year.